{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(10)"],"submitter":["Li G"],"funding":["Hebei Province Health Commission","National Natural Science Foundation of China","Hebei Provincial Department of Human Resources and Social Security"],"pubmed_abstract":["<h4>Background</h4>Advanced non-small cell lung cancer (NSCLC) is often complicated by leptomeningeal metastases (LMs), especially in patients carrying EGFR mutations. EGFR tyrosine kinase inhibitors (TKIs) are the first-line drug for patients with specific gene mutations, such as EGFR exon 19 deletion or exon 21 L858R mutation. However, after long-term TKI use, patients eventually develop drug resistance and acquire new mutations. Acquiring the EGFR T790 M mutation during TKI treatment is a marker for first/second generation TKI resistance. Osimertinib (a third-generation TKI) could overcome this resistance, especially for patients who have already developed NSCLC-LM. Treating NSCLC patients with osimertinib resistance is challenging. Our aim was to investigate whether afatinib is effecti"],"journal":["Heliyon"],"pagination":["e20690"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10582297"],"repository":["biostudies-literature"],"pubmed_title":["Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports."],"pmcid":["PMC10582297"],"pubmed_authors":["Li G","Liu X","Mei F","Fang M","Zhou Y","Tian P"],"additional_accession":[]},"is_claimable":false,"name":"Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports.","description":"<h4>Background</h4>Advanced non-small cell lung cancer (NSCLC) is often complicated by leptomeningeal metastases (LMs), especially in patients carrying EGFR mutations. EGFR tyrosine kinase inhibitors (TKIs) are the first-line drug for patients with specific gene mutations, such as EGFR exon 19 deletion or exon 21 L858R mutation. However, after long-term TKI use, patients eventually develop drug resistance and acquire new mutations. Acquiring the EGFR T790 M mutation during TKI treatment is a marker for first/second generation TKI resistance. Osimertinib (a third-generation TKI) could overcome this resistance, especially for patients who have already developed NSCLC-LM. Treating NSCLC patients with osimertinib resistance is challenging. Our aim was to investigate whether afatinib is effecti","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Oct","modification":"2025-04-04T11:00:36.463Z","creation":"2025-04-04T11:00:36.463Z"},"accession":"S-EPMC10582297","cross_references":{"pubmed":["37860534"],"doi":["10.1016/j.heliyon.2023.e20690"]}}